NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

Angelman氏症候群 - 市場分析,流行病學,市場預測 2028年

Angelman syndrome - Market Insights, Epidemiology and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 868386
出版日期 按訂單生產 內容資訊 英文 128 Pages
商品交期: 2-10個工作天內
價格
Angelman氏症候群 - 市場分析,流行病學,市場預測 2028年 Angelman syndrome - Market Insights, Epidemiology and Market Forecast - 2028
出版日期: 按訂單生產內容資訊: 英文 128 Pages
簡介

本報告提供主要7國(美國,英國,德國,法國,義大利,西班牙,日本)的Angelman氏症候群市場調查,總括性彙整疾病概要和現行的治療方法,新藥的簡介,以整體及各國的市場趨勢,流行病學的預測,市場規模,患病數·罹患數的變化與預測,未滿足需求,市場成長要素及障礙等資訊。

目錄

第1章 市場考察

第2章 疾病概要:Angelman氏症候群

  • 市場佔有率(實際成果值)
  • 市場佔有率(預測值)

第3章 疾病背景和概要

  • 簡介
  • 原因
  • 徵兆與症狀
  • 相關障礙與鑑別診斷
  • 併發症
  • Angelman氏症候群的遺傳學
  • 分子遺傳病理學
  • 診斷
    • 診斷的臨床標準
    • 病歷和病情
  • 診斷演算法

第4章 流行病學及患者人口

  • 主要調查結果

第5章 主要7國Angelman氏症候群的整體患病數

第6章 Angelman氏症候群的流行病學:各國

  • 美國
    • 假設和理論的根據
    • 整體患病數
    • Angelman氏症候群伴隨的出生數
    • Angelman氏症候群的成人患病數
    • Angelman氏症候群的診斷患病數
    • Angelman氏症候群的病例數:各畸形類型
    • Angelman氏症候群臨床症狀
  • 歐盟5國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第7章 Angelman氏症候群的治療和管理

  • Angelman氏症候群管理上建議

第8章 未滿足需求

第9章 新藥

  • gabokisadoru:OVID THERAPEUTICS
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介

第10章 Angelman氏症候群:主要7國的市場分析

  • 主要調查結果
  • Angelman氏症候群的市場規模
    • Angelman氏症候群的市場規模:各治療藥物

第11章 Angelman氏症候群市場預測:各國

第12章 美國的Angelman氏症候群市場預測

  • 市場規模
    • 整體市場規模
    • 市場規模:各治療藥物

第13章 歐盟5國的Angelman氏症候群市場預測

  • 德國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 法國
    • 整體市場規模
    • 市場規模:各治療藥物
  • 義大利
    • 整體市場規模
    • 市場規模:各治療藥物
  • 西班牙
    • 整體市場規模
    • 市場規模:各治療藥物
  • 英國
    • 整體市場規模
    • 市場規模:各治療藥物

第14章 日本的Angelman氏症候群市場預測

  • 整體市場規模
  • 市場規模:各治療藥物

第15章 市場成長要素

第16章 市場障礙

第17章 附錄

  • 調查手法

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

目錄
Product Code: DIMI0357

DelveInsight's 'Angelman syndrome - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Angelman syndrome in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Angelman syndrome from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Angelman syndrome - Disease Understanding and Treatment Algorithm

According to NORD (National Organization of Rare Disorders), Angelman syndrome is a rare genetic and neurological disorder characterized by severe developmental delays and learning disabilities, absence or near absence of speech, inability to coordinate voluntary movements (ataxia), tremulousness with jerky movements of the arms and legs, a distinctive behavioral pattern characterized by a happy disposition and unprovoked episodes of laughter and smiling, people with Angelman syndrome are usually happy and affectionate and may laugh often and at inappropriate times, affected people may also have epilepsy, is often associated with low levels of pigment in skin, hair and eyes.

Individuals affected with the syndrome unable to speak, many gradually learn to communicate through other means such as gesturing. In addition, children may have enough receptive language ability to understand simple forms of language communication. Additional symptoms may occur including seizures, sleep disorders and feeding difficulties. Some children with Angelman syndrome may have distinctive facial features but most facial features reflect the normal parental traits. Angelman syndrome is caused by deletion or abnormal expression of the UBE3A gene. Angelman syndrome occurs when only one copy of the gene is active in certain areas of the brain.

The DelveInsight Angelman syndrome market report gives the thorough understanding of the Angelman syndrome by including details such as disease definition, cause, signs and symptoms, complications, genetics, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Angelman syndrome in the US, Europe, and Japan.

Angelman syndrome Epidemiology

The Angelman syndrome epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by Total Prevalent Cases of Angelman syndrome, Live Birth Cases of Angelman syndrome, Adult Prevalent Cases of Angelman syndrome, Diagnosed Prevalent Cases of Angelman syndrome, Angelman syndrome cases by Mutation Types, Angelman syndrome associated Clinical Manifestations.

According to DelveInsight, the prevalent cases of Angelman syndrome was 58,351 cases in 2017 in 7 MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2017-2028. Among 7MM, United States account for highest prevalent cases of Angelman syndrome with 21,966 prevalent cases in 2017. This trend is expected to increase during the study period.

Angelman syndrome Drug Chapters

This segment of the Angelman syndrome report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. This report includes detailed chapters of promising upcoming therapies.

Angelman syndrome Market Outlook

The Angelman syndrome market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Angelman syndrome market is expected to grow during the forecasted period of 2019-2028 at a CAGR of XX% owing to the launch of few drugs (presently in Phase III and Phase II). Angelman syndrome therapeutics market has seen a 7MM sales of USD 274.8 Million in 2017.

Angelman syndrome Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Angelman syndrome Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Angelman syndrome Report Key Strengths

  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Angelman syndrome Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Angelman syndrome market
  • Organize sales and marketing efforts by identifying the best opportunities for Angelman syndrome market
  • To understand the future market competition in the Angelman syndrome market.

Table of Contents

1. KEY INSIGHTS

2. ANGELMAN SYNDROME MARKET OVERVIEW AT A GLANCE

  • 2.1 MARKET SHARE (%) DISTRIBUTION OF ANGELMAN SYNDROME IN 2017
  • 2.2 MARKET SHARE (%) DISTRIBUTION OF ANGELMAN SYNDROME IN 2028

3. DISEASE BACKGROUND AND OVERVIEW

  • 3.1 INTRODUCTION
  • 3.2 CAUSE
  • 3.3 SIGNS AND SYMPTOMS
  • 3.4 RELATED DISORDERS AND DIFFERENTIAL DIAGNOSIS
  • 3.5 COMPLICATIONS
  • 3.5 GENETICS OF ANGELMAN SYNDROME
  • 3.6 MOLECULAR GENETIC PATHOGENESI
  • 3.7 DIAGNOSIS
    • 3.1.1 Clinical criteria for diagnosis
    • 3.1.2 Disease History and Medical Conditions
  • 3.3 DIAGNOSTIC ALGORITHM

4. EPIDEMIOLOGY AND PATIENT POPULATION

  • 4.1 KEY FINDINGS

5. 7MM TOTAL PREVALENT PATIENT POPULATION OF ANGELMAN SYNDROME

6. COUNTRY WISE-EPIDEMIOLOGY OF ANGELMAN SYNDROME

  • 6.1 THE UNITED STATES
    • 6.1.1 Assumptions and Rationale
    • 6.1.2 Total Prevalent Cases of Angelman syndrome in the United States
    • 6.1.3 Live Birth Cases of Angelman syndrome in the United States
    • 6.1.4 Adult Prevalent Cases of Angelman syndrome in the United States
    • 6.1.5 Diagnosed Prevalent Cases of Angelman syndrome in the United States
    • 6.1.6 Angelman syndrome cases by Mutation Types in the United States
    • 6.1.7 Angelman syndrome associated Clinical Manifestations in the United States
  • 6.2 EU5
    • 6.2.1 Assumptions and Rationale
  • 6.3 GERMANY
    • 6.3.1 Total Prevalent Cases of Angelman syndrome in Germany
    • 6.3.2 Live Birth Cases of Angelman syndrome in Germany
    • 6.3.3 Adult Prevalent Cases of Angelman syndrome in Germany
    • 6.3.4 Diagnosed Prevalent Cases of Angelman syndrome in Germany
    • 6.3.5 Angelman syndrome cases by Mutation Types in Germany
    • 6.3.6 Angelman syndrome associated Clinical Manifestations in Germany
  • 6.4 FRANCE
    • 6.4.1 Total Prevalent Cases of Angelman syndrome in France
    • 6.4.2 Live Birth Cases of Angelman syndrome in France
    • 6.4.3 Adult Prevalent Cases of Angelman syndrome in France
    • 6.4.4 Diagnosed Prevalent Cases of Angelman syndrome in France
    • 6.4.5 Angelman syndrome cases by Mutation Types in France
    • 6.4.6 Angelman syndrome associated Clinical Manifestations in France
  • 6.5 ITALY
    • 6.5.1 Total Prevalent Cases of Angelman syndrome in Italy
    • 6.5.2 Live Birth Cases of Angelman syndrome in Italy
    • 6.5.3 Adult Prevalent Cases of Angelman syndrome in Italy
    • 6.5.4 Diagnosed Prevalent Cases of Angelman syndrome in Italy
    • 6.5.5 Angelman syndrome cases by Mutation Types in Italy
    • 6.5.6 Angelman syndrome associated Clinical Manifestations in Italy
  • 6.6 SPAIN
    • 6.6.1 Total Prevalent Cases of Angelman syndrome in Spain
    • 6.6.2 Live Birth Cases of Angelman syndrome in Spain
    • 6.6.3 Adult Prevalent Cases of Angelman syndrome in Spain
    • 6.6.4 Diagnosed Prevalent Cases of Angelman syndrome in Spain
    • 6.6.5 Angelman syndrome cases by Mutation Types in Spain
    • 6.6.6 Angelman syndrome associated Clinical Manifestations in Spain
  • 6.7 THE UNITED KINGDOM
    • 6.7.1 Total Prevalent Cases of Angelman syndrome in the United Kingdom
    • 6.7.2 Live Birth Cases of Angelman syndrome in the UK
    • 6.7.3 Adult Prevalent Cases of Angelman syndrome in the UK
    • 6.7.4 Diagnosed Prevalent Cases of Angelman syndrome in the United Kingdom
    • 6.7.5 Angelman syndrome cases by Mutation Types in the UK
    • 6.7.6 Angelman syndrome associated Clinical Manifestations in the UK
  • 6.8 JAPAN
    • 6.8.1 Assumptions and Rationale
    • 6.8.2 Total Prevalent Cases of Angelman syndrome in Japan
    • 6.8.3 Live Birth Cases of Angelman syndrome in Japan
    • 6.8.4 Adult Prevalent Cases of Angelman syndrome in Japan
    • 6.8.5 Diagnosed Prevalent Cases of Angelman syndrome in Japan
    • 6.8.6 Angelman syndrome cases by Mutation Types in Japan
    • 6.8.7 Angelman syndrome associated Clinical Manifestations in Japan

7. TREATMENT AND MANAGEMENT OF ANGELMAN SYNDROME

  • 7.1 RECOMMENDATIONS FOR THE MANAGEMENT OF ANGELMAN SYNDROME

8. UNMET NEEDS

9. EMERGING THERAPIES

  • 9.1 GABOXADOL: OVID THERAPEUTICS
    • 9.1.1 Product Description
    • 9.1.2 Other Development Activities
    • 9.1.3 Clinical Developmen
    • 9.1.4 Safety and Efficac
    • 9.1.5 Product Profile

10. ANGELMAN SYNDROME: 7 MAJOR MARKET ANALYSIS

  • 10.1 KEY FINDINGS
  • 10.2 MARKET SIZE OF ANGELMAN SYNDROME IN 7MM
    • 10.2.1 Market Size of Angelman syndrome by Therapies

11. MARKET OUTLOOK BY COUNTRY

12. THE UNITED STATES: MARKET OUTLOOK

  • 12.1 UNITED STATES MARKET SIZE
    • 12.1.1 Total Market Size of Angelman syndrome
    • 12.1.2 Market Size of Angelman Syndrome by Therapies

13. EU-5 COUNTRIES: MARKET OUTLOOK

  • 13.1 GERMANY
    • 13.1.1 Total Market size of Angelman syndrome
    • 13.1.2 Market Size of Angelman Syndrome by Therapies
  • 13.2 FRANCE
    • 13.2.1 Total Market Size of Angelman syndrome
    • 13.2.2 Market Size of Angelman Syndrome by Therapies
  • 13.3 ITALY
    • 13.3.1 Total Market Size of Angelman syndrome
    • 13.3.2 Market Size of Angelman Syndrome by Therapies
  • 13.4 SPAIN
    • 13.4.1 Total Market Size of Angelman syndrome
    • 13.4.2 Market Size of Angelman Syndrome by Therapies
  • 13.5 UNITED KINGDOM
    • 13.5.1 Total Market Size of Angelman syndrome
    • 13.5.2 Market Size of Angelman syndrome by Therapies

14. JAPAN: MARKET OUTLOOK

    • 14.1.1 Total Market Size of Angelman syndrome
    • 14.1.2 Market Size of Angelman syndrome by Therapies

15. MARKET DRIVERS

16. MARKET BARRIERS

17. APPENDIX

  • 17.1 REPORT METHODOLOGY

18. DELVEINSIGHT CAPABILITIES

19. DISCLAIMER

20. ABOUT DELVEINSIGHT

List of Tables

  • TABLE 1: MOLECULAR GENETIC TESTING USED IN AS AFTER DNA METHYLATION ANALYSIS
  • TABLE 2: PREVALENT PATIENT POPULATION OF ANGELMAN SYNDROME IN 7MM (2017-2028
  • TABLE 3: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
  • TABLE 4: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
  • TABLE 5: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
  • TABLE 6: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
  • TABLE 7: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN THE UNITED STATES (2017-2028)
  • TABLE 8: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN THE UNITED STATES (2017-2028)
  • TABLE 9: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
  • TABLE 10: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
  • TABLE 11: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
  • TABLE 12: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
  • TABLE 13: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN GERMANY (2017-2028)
  • TABLE 14: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN GERMANY (2017-2028)
  • TABLE 15: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
  • TABLE 16: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
  • TABLE 17: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
  • TABLE 18: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
  • TABLE 19: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN FRANCE (2017-2028)
  • TABLE 20: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN FRANCE (2017-2028)
  • TABLE 21: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
  • TABLE 22: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
  • TABLE 23: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
  • TABLE 24: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
  • TABLE 25: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN ITALY (2017-2028)
  • TABLE 26: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN ITALY (2017-2028)
  • TABLE 27: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
  • TABLE 28: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
  • TABLE 29: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
  • TABLE 30: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
  • TABLE 31: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN SPAIN (2017-2028)
  • TABLE 32: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN SPAIN (2017-2028)
  • TABLE 33: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED KINGDOM (2017-2028)
  • TABLE 34: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN THE UK (2017-2028)
  • TABLE 35: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN THE UK (2017-2028)
  • TABLE 36: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED KINGDOM (2017-2028)
  • TABLE 37: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN THE UK (2017-2028)
  • TABLE 38: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN THE UK (2017-2028)
  • TABLE 39: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
  • TABLE 40: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
  • TABLE 41: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
  • TABLE 42: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
  • TABLE 43: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN JAPAN (2017-2028)
  • TABLE 44: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN JAPAN (2017-2028)
  • TABLE 45: FEEDING & DIET RECOMMENDATIONS
  • TABLE 46: DEVELOPMENT RECOMMENDATIONS
  • TABLE 47: SEIZURE TYPES-THE FOLLOWING ARE TYPICAL OF AS:
  • TABLE 48: TREATMENT FOR SEIZURES AND CNS
  • TABLE 49: AGE RECOMMENDATIONS
  • TABLE 50: AGE RECOMMENDATIONS
  • TABLE 51: AGE RECOMMENDATIONS
  • TABLE 52: AGE RECOMMENDATIONS
  • TABLE 53: AGE RECOMMENDATIONS
  • TABLE 54: GENERAL HEALTH & ANAESTHESIA RECOMMENDATIONS
  • TABLE 55: SCOLIOSIS & SKELETAL RECOMMENDATIONS
  • TABLE 56: PUBERTY & SEXUAL HEALTH RECOMMENDATIONS
  • TABLE 57: GABOXADOL, CLINICAL TRIAL DESCRIPTION, 2018
  • TABLE 58: 7 MAJOR MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
  • TABLE 59: 7 MAJOR MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • TABLE 60: UNITED STATES MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
  • TABLE 61: THE US MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • TABLE 62: GERMANY MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
  • TABLE 63: GERMANY MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • TABLE 64: FRANCE MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
  • TABLE 65: FRANCE MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • TABLE 66: ITALY MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
  • TABLE 67: ITALY MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • TABLE 68: SPAIN MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
  • TABLE 69: SPAIN MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • TABLE 70: UNITED KINGDOM MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
  • TABLE 71: THE UK MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • TABLE 72: JAPAN MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
  • TABLE 73: JAPAN MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)

List of Figures

  • FIGURE 1: IMPRINTING MAP OF PATERNAL AND MATERNAL HUMAN CHROMOSOME 15Q11-13 AROUND AS-1C
  • FIGURE 2: DIAGNOSTIC ALGORITHM
  • FIGURE 3: PREVALENT PATIENT POPULATION OF ANGELMAN SYNDROME IN 7MM (2017-2028)
  • FIGURE 4: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
  • FIGURE 5: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
  • FIGURE 6: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
  • FIGURE 7: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED STATES (2017-2028)
  • FIGURE 8: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN THE UNITED STATES (2017-2028)
  • FIGURE 9: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN THE UNITED STATES (2017-2028)
  • FIGURE 10: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
  • FIGURE 11: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
  • FIGURE 12: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
  • FIGURE 13: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN GERMANY (2017-2028)
  • FIGURE 14: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN GERMANY (2017-2028)
  • FIGURE 15: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN GERMANY (2017-2028)
  • FIGURE 16: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
  • FIGURE 17: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
  • FIGURE 18: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
  • FIGURE 19: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN FRANCE (2017-2028)
  • FIGURE 20: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN FRANCE (2017-2028)
  • FIGURE 21: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN FRANCE (2017-2028)
  • FIGURE 22: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
  • FIGURE 23: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
  • FIGURE 24: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
  • FIGURE 25: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN ITALY (2017-2028)
  • FIGURE 26: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN ITALY (2017-2028)
  • FIGURE 27: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN ITALY (2017-2028)
  • FIGURE 28: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
  • FIGURE 29: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
  • FIGURE 30: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
  • FIGURE 31: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN SPAIN (2017-2028)
  • FIGURE 32: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN SPAIN (2017-2028)
  • FIGURE 33: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN SPAIN (2017-2028)
  • FIGURE 34: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED KINGDOM (2017-2028)
  • FIGURE 35: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN THE UK (2017-2028)
  • FIGURE 36: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN THE UK (2017-2028)
  • FIGURE 37: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN THE UNITED KINGDOM (2017-2028)
  • FIGURE 38: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN THE UK (2017-2028)
  • FIGURE 39: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN THE UK (2017-2028)
  • FIGURE 40: TOTAL PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
  • FIGURE 41: LIVE BIRTH CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
  • FIGURE 42: ADULT PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
  • FIGURE 43: DIAGNOSED PREVALENT CASES OF ANGELMAN SYNDROME IN JAPAN (2017-2028)
  • FIGURE 44: ANGELMAN SYNDROME CASES BY MUTATION TYPES IN JAPAN (2017-2028)
  • FIGURE 45: ANGELMAN SYNDROME ASSOCIATED CLINICAL MANIFESTATIONS IN JAPAN (2017-2028)
  • FIGURE 46: UNMET NEEDS OF ANGELMAN SYNDROME
  • FIGURE 47: 7 MAJOR MARKET SIZE OF ANGELMAN SYNDROME IN USD MILLION (2017-2028)
  • FIGURE 48: 7 MAJOR MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • FIGURE 49: MARKET SIZE OF ANGELMAN SYNDROME IN THE UNITED STATES, USD MILLION (2017-2028)
  • FIGURE 50: THE US MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • FIGURE 51: MARKET SIZE OF ANGELMAN SYNDROME IN GERMANY, USD MILLION (2017-2028)
  • FIGURE 52: GERMANY MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028
  • FIGURE 53: MARKET SIZE OF ANGELMAN SYNDROME IN FRANCE USD MILLION (2017-2028)
  • FIGURE 54: FRANCE MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • FIGURE 55: MARKET SIZE OF ANGELMAN SYNDROME IN ITALY, USD MILLION (2017-2028)
  • FIGURE 56: ITALY MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • FIGURE 57: MARKET SIZE OF ANGELMAN SYNDROME IN SPAIN, USD MILLION (2017-2028)
  • FIGURE 58: SPAIN MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • FIGURE 59: MARKET SIZE OF ANGELMAN SYNDROME IN THE UNITED KINGDOM, USD MILLION (2017-228)
  • FIGURE 60: THE UK MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • FIGURE 61: MARKET SIZE OF ANGELMAN SYNDROME IN JAPAN, USD MILLION (2017-2028)
  • FIGURE 62: JAPAN MARKET SIZE OF ANGELMAN SYNDROME BY THERAPIES IN USD MILLION (2017-2028)
  • FIGURE 63: MARKET DRIVERS
  • Figure 64: Market Barriers